Cite
MLA Citation
Charles M Rudin et al.. “Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.” Lancet oncology, vol. 18, no. 1, n.d., pp. 42–51. http://access.bl.uk/ark:/81055/vdc_100039989298.0x000034